NCT00680173View on ClinicalTrials.gov

Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Chronic Hepatitis C
Interventions
DRUG

pegylated interferon alpha 2a and plus ribavirin

pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT00680173 - Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients | Biotech Hunter | Biotech Hunter